AVITA Medical (RCEL) Stock Forecast, Price Target & Predictions
RCEL Stock Forecast
AVITA Medical stock forecast is as follows: an average price target of $14.00 (represents a 48.94% upside from RCEL’s last price of $9.40) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
RCEL Price Target
The average price target for AVITA Medical (RCEL) is $14.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 48.94% upside from RCEL's last price of $9.40.
RCEL Analyst Ratings
According to 6 Wall Street analysts, AVITA Medical's rating consensus is 'Buy'. The analyst rating breakdown for RCEL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AVITA Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 08, 2025 | Brooks O'Neil | Lake Street | $14.00 | $14.06 | -0.43% | 48.94% |
| May 14, 2024 | Matt O'Brien | Piper Sandler | $9.00 | $8.35 | 7.78% | -4.26% |
The latest AVITA Medical stock forecast, released on Jan 08, 2025 by Brooks O'Neil from Lake Street, set a price target of $14.00, which represents a -0.43% decrease from the stock price at the time of the forecast ($14.06), and a 48.94% increase from RCEL last price ($9.40).
AVITA Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $14.00 | $14.00 | $11.50 |
| Last Closing Price | $9.40 | $9.40 | $9.40 |
| Upside/Downside | 48.94% | 48.94% | 22.34% |
In the current month, the average price target of AVITA Medical stock is $14.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 48.94% increase as opposed to AVITA Medical's last price of $9.40. This month's average price target is down 0.00% compared to last quarter, and up 21.74% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 08, 2025 | Lake Street | Buy | Buy | Hold |
| Dec 24, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Aug 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 14, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 14, 2024 | Piper Sandler | Neutral | Downgrade | |
| Jun 27, 2023 | Cantor Fitzgerald | Overweight | Initialise | |
| Jun 16, 2021 | BTIG | Buy | Buy | Hold |
AVITA Medical's last stock rating was published by Lake Street on Jan 08, 2025. The company gave RCEL a "Buy" rating, the same as its previous rate.
AVITA Medical Financial Forecast
AVITA Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.64M | $11.75M | $10.55M | $9.46M | $9.09M | $8.34M | $7.54M | $6.94M | $7.02M | $10.30M | $8.77M | $5.10M | $5.06M | $3.88M |
| Avg Forecast | $17.26M | $17.54M | $17.82M | $18.10M | $30.96M | $28.05M | $24.31M | $21.40M | $20.72M | $19.44M | $14.52M | $11.08M | $14.20M | $13.40M | $11.30M | $10.28M | $8.80M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| High Forecast | $19.43M | $19.74M | $20.06M | $20.38M | $34.86M | $31.58M | $27.37M | $24.09M | $23.32M | $21.89M | $16.34M | $12.47M | $15.89M | $15.09M | $12.72M | $11.57M | $9.43M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| Low Forecast | $16.24M | $16.50M | $16.77M | $17.04M | $29.14M | $26.40M | $22.88M | $20.14M | $19.50M | $18.30M | $13.66M | $10.43M | $13.36M | $12.61M | $10.63M | $9.67M | $8.18M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.04% | 1.03% | 1.07% | 1.21% | 1.14% | 1.04% | 0.84% | 0.96% | 2.09% | 1.72% | 1.32% | 0.64% | 1.07% |
AVITA Medical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.20M, with a low forecast of $13.36M, and a high forecast of $15.89M. RCEL's average Quarter revenue forecast represents a 4.03% increase compared to the company's last Quarter revenue of $13.64M (Sep 23).
AVITA Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.53M | $8.31M | $-9.05M | $-5.19M | $-5.44M | $-6.12M | $-9.46M | $-8.45M | $-5.76M | $-4.53M | $-5.82M | $-5.46M | $-10.00M | $-12.90M |
| Avg Forecast | $-16.51M | $-16.77M | $-17.04M | $-17.32M | $-29.61M | $-26.83M | $-23.25M | $-20.47M | $-19.82M | $-18.59M | $-13.89M | $-11.82M | $-13.58M | $-12.82M | $-10.81M | $-12.22M | $-12.28M | $-7.16M | $-7.00M | $-11.69M | $-7.92M | $-7.01M | $-4.72M | $-8.66M | $-3.71M | $-7.62M | $-10.24M |
| High Forecast | $-15.54M | $-15.79M | $-16.04M | $-16.30M | $-27.87M | $-25.25M | $-21.88M | $-19.26M | $-18.65M | $-17.50M | $-13.07M | $-9.46M | $-12.78M | $-12.06M | $-10.17M | $-9.78M | $-9.82M | $-7.16M | $-7.00M | $-9.35M | $-7.92M | $-7.01M | $-4.72M | $-6.92M | $-3.71M | $-7.62M | $-8.19M |
| Low Forecast | $-18.59M | $-18.88M | $-19.19M | $-19.49M | $-33.34M | $-30.21M | $-26.18M | $-23.04M | $-22.31M | $-20.94M | $-15.63M | $-14.18M | $-15.20M | $-14.43M | $-12.17M | $-14.66M | $-14.73M | $-7.16M | $-7.00M | $-14.03M | $-7.92M | $-7.01M | $-4.72M | $-10.39M | $-3.71M | $-7.62M | $-12.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | -0.77% | 0.74% | 0.42% | 0.76% | 0.87% | 0.81% | 1.07% | 0.82% | 0.96% | 0.67% | 1.47% | 1.31% | 1.26% |
4 analysts predict RCEL's average Quarter EBITDA for Sep 23 to be $-12.82M, with a high of $-12.06M and a low of $-14.43M. This is -254.22% lower than AVITA Medical's previous annual EBITDA (Jun 23) of $8.31M.
AVITA Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.71M | $-10.38M | $-9.22M | $-5.35M | $-5.59M | $-6.26M | $-9.46M | $-8.48M | $-5.95M | $-4.72M | $-6.00M | $-5.64M | $-10.23M | $-12.91M |
| Avg Forecast | $-4.08M | $-4.08M | $-8.16M | $-8.16M | $-1.72M | $-4.10M | $-9.26M | $-13.63M | $-17.52M | $-15.94M | $-18.32M | $-12.03M | $-14.12M | $-17.27M | $-11.97M | $-12.44M | $-12.67M | $-13.00M | $-12.67M | $-11.90M | $-10.23M | $-12.28M | $-16.52M | $-8.92M | $-5.41M | $-4.74M | $-10.25M |
| High Forecast | $-3.77M | $-3.77M | $-7.54M | $-7.54M | $-1.59M | $-3.78M | $-8.55M | $-12.58M | $-11.68M | $-14.72M | $-16.91M | $-9.63M | $-13.04M | $-15.95M | $-11.06M | $-9.95M | $-10.14M | $-13.00M | $-12.67M | $-9.52M | $-10.23M | $-12.28M | $-16.52M | $-7.14M | $-5.41M | $-4.74M | $-8.20M |
| Low Forecast | $-4.75M | $-4.75M | $-9.50M | $-9.50M | $-2.00M | $-4.77M | $-10.78M | $-15.86M | $-23.36M | $-18.55M | $-21.31M | $-14.44M | $-16.43M | $-20.10M | $-13.93M | $-14.93M | $-15.21M | $-13.00M | $-12.67M | $-14.28M | $-10.23M | $-12.28M | $-16.52M | $-10.71M | $-5.41M | $-4.74M | $-12.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.74% | 0.42% | 0.43% | 0.49% | 0.80% | 0.83% | 0.48% | 0.29% | 0.67% | 1.04% | 2.16% | 1.26% |
AVITA Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCEL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AVITA Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.66M | $-3.84M | $14.84M | $11.66M | $10.41M | $10.80M | $12.36M | $10.60M | $8.87M | $9.42M | $9.07M | $7.00M | $11.74M | $14.67M |
| Avg Forecast | $127.28M | $129.32M | $131.39M | $133.50M | $228.32M | $206.85M | $179.27M | $157.79M | $152.78M | $143.36M | $107.05M | $81.71M | $104.68M | $98.82M | $83.33M | $75.81M | $64.90M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| High Forecast | $143.29M | $145.59M | $147.93M | $150.30M | $257.06M | $232.88M | $201.83M | $177.65M | $172.01M | $161.41M | $120.53M | $91.99M | $117.19M | $111.26M | $93.82M | $85.35M | $69.55M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| Low Forecast | $119.78M | $121.71M | $123.66M | $125.64M | $214.89M | $194.67M | $168.72M | $148.50M | $143.78M | $134.92M | $100.75M | $76.90M | $98.50M | $93.00M | $78.43M | $71.35M | $60.33M | $55.19M | $53.96M | $53.39M | $61.02M | $54.02M | $36.41M | $37.61M | $28.61M | $58.76M | $26.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.17% | -0.05% | 0.20% | 0.18% | 0.19% | 0.20% | 0.23% | 0.17% | 0.16% | 0.26% | 0.24% | 0.24% | 0.20% | 0.55% |
AVITA Medical's average Quarter SG&A projection for Dec 23 is $104.68M, based on 5 Wall Street analysts, with a range of $98.50M to $117.19M. The forecast indicates a 528.50% rise compared to RCEL last annual SG&A of $16.66M (Sep 23).
AVITA Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.41 | $-0.37 | $-0.24 | $-0.22 | $-0.25 | $-0.38 | $-0.34 | $-0.24 | $-0.19 | $-0.26 | $-0.26 | $-0.48 | $-0.61 |
| Avg Forecast | $-0.16 | $-0.16 | $-0.32 | $-0.32 | $-0.07 | $-0.16 | $-0.36 | $-0.54 | $-0.69 | $-0.63 | $-0.72 | $-0.53 | $-0.56 | $-0.68 | $-0.47 | $-0.40 | $-0.35 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| High Forecast | $-0.15 | $-0.15 | $-0.30 | $-0.30 | $-0.06 | $-0.15 | $-0.34 | $-0.50 | $-0.46 | $-0.58 | $-0.67 | $-0.49 | $-0.51 | $-0.63 | $-0.44 | $-0.37 | $-0.32 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| Low Forecast | $-0.19 | $-0.19 | $-0.37 | $-0.37 | $-0.08 | $-0.19 | $-0.42 | $-0.62 | $-0.92 | $-0.73 | $-0.84 | $-0.62 | $-0.65 | $-0.79 | $-0.55 | $-0.47 | $-0.39 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.92% | 0.68% | 0.43% | 0.50% | 0.82% | 0.84% | 0.50% | 0.29% | 0.74% | 1.22% | 2.57% | 3.07% |
According to undefined Wall Street analysts, AVITA Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCEL previous annual EPS of $NaN (undefined).
AVITA Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.46 | $8.50 | 482.19% | Buy |
| TELA | TELA Bio | $2.77 | $8.00 | 188.81% | Buy |
| SGHT | Sight Sciences | $3.05 | $7.50 | 145.90% | Hold |
| LUNG | Pulmonx | $5.83 | $13.00 | 122.98% | Buy |
| RXST | RxSight | $31.58 | $70.14 | 122.10% | Buy |
| TMDX | TransMedics Group | $65.53 | $110.60 | 68.78% | Buy |
| RCEL | AVITA Medical | $9.40 | $14.00 | 48.94% | Buy |
| DCTH | Delcath Systems | $15.65 | $22.00 | 40.58% | Buy |
| TMCI | Treace Medical Concepts | $10.42 | $14.50 | 39.16% | Buy |
| OFIX | Orthofix Medical | $18.71 | $24.00 | 28.27% | |
| CLPT | ClearPoint Neuro | $17.79 | $22.50 | 26.48% | Buy |
| VREX | Varex Imaging | $13.60 | $17.00 | 25.00% | Buy |
| SIBN | SI-BONE | $17.22 | $18.50 | 7.43% | Buy |
| NPCE | NeuroPace | $14.69 | $15.00 | 2.11% | Buy |
| IRMD | IRadimed | $59.85 | $60.00 | 0.25% | Buy |
| CVRX | CVRx | $16.85 | $15.00 | -10.98% | Buy |